Research Update CHF 02783 EY1: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 EY1: Transcriptional Profiling of Canine Soft Tissue Sarcoma”

Research Update CHF 02780 EY1: Bladder Carcinogen Exposures in Pet Dogs

Right after our AKC Canine Health Foundation grant funding started in March 2020, our lab was closed for 3 months due to COVD-19 and has since been limited to 50% occupancy. In addition, our teaching hospital has had limited appointments since March 2020.

We finished a few validation experiments on our DNA damage assays that were needed before recruitment, and we have started recruiting dogs with bladder cancer and matched controls. We enrolled our first two new cases and two controls this month. Continue reading “Research Update CHF 02780 EY1: Bladder Carcinogen Exposures in Pet Dogs”

Research Update CHF 02758 EY1: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms

Thank you for supporting our project titled “Optical coherence tomography for margin evaluation of skin and subcutaneous neoplasms”. This project is investigating an emerging diagnostic imaging tool, optical coherence tomography that uses light waves to generate real time high-resolution images of tissues for detection of residual cancer cells immediately following surgical removal. Our team involves collaboration between veterinary medicine and pathology at the Ohio State University. We have had excellent progress in our patient enrollment, we completed enrollment of the 80 cases planned already! Continue reading “Research Update CHF 02758 EY1: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms”

Research Update CHF 02502 EY3: Precision Medicine for Canine Lymphoma

We have successfully developed a canine cancer gene panel that we have called the Canine Oncopanel,  using cutting-edge, next-generation sequencing technology (NGS). The Canine Oncopanel allows sequencing of 283 cancer-related genes and detection of mutations within these genes that may drive the tumor cells to proliferate and survive. The canine oncopanel sequences a total target region that equates to ~3% of the canine genome. Analyzing the genomic composition of this broad target region allows evaluation of common genomic alterations that can lead to the development of cancer. The Canine Oncopanel is suitable to map mutation profiles and identify driver mechanisms in both common and rare canine cancers to provide a better understanding of the tumor genome and its biology.

Continue reading “Research Update CHF 02502 EY3: Precision Medicine for Canine Lymphoma”

Research Update MAF D16CA-056 Final: Measuring Chemotherapy Drug Resistance in Dogs with T-cell Lymphoma

RESULTS: New Technology Helps Detect Small Amounts of Drug-Resistant Cancer Cells in Dogs with T-cell Lymphoma.

Morris Animal Foundation-funded researchers from North Carolina State University used state-of-the-art DNA technology to help detect small amounts of drug-resistant cancer cells that persist after treatment in dogs with T-cell lymphoma (minimal residual disease, MRD). Accurately monitoring MRD could provide a fuller picture of the effectiveness of different drugs and improve treatment success, quality of life and survival for these patients. Continue reading “Research Update MAF D16CA-056 Final: Measuring Chemotherapy Drug Resistance in Dogs with T-cell Lymphoma”

Research Update CHF 02806-MOU MY1: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention in 12 of these dogs. Continue reading “Research Update CHF 02806-MOU MY1: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02751-A EY1: Luteinizing Hormone Receptor Activation Induces Migration and Adhesion in Neoplastic Canine Lymphocytes

In the United States, spaying and neutering of dogs and cats is commonly performed to prevent the birth of unwanted pets. However, surgically removing the ovaries or testes may have unexpected consequences. Dogs that have been spayed or neutered have an increased risk for developing obesity, urinary incontinence, hypothyroidism, hyperadrenocorticism, diabetes, cruciate ligament tears, hip dysplasia, and cancer. Lymphoma is three to four times more common in spayed and neutered dogs compared to dogs left intact. In addition, dogs that are neutered before one year of age are three times more likely to develop lymphoma than dogs neutered after one year of age. This funded study is investigating the hormonal and cellular relationships between spaying/neutering and the development of lymphoma so that in the future new treatments will be available to extend life expectancies of dogs with cancer.

End-Year-1 Research Update Dr. Kutzler at early spay/neuter and neoplasia.

Research Update CHF 02519 EY3: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. Continue reading “Research Update CHF 02519 EY3: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”

Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

During the first 18 months of the trial, we have made progress toward our objectives. The project goals have not been modified.

Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Continue reading “Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02643-A MY2: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity

We have completed a lot of the proposed work related to the effects of CBD on cell death and autophagy and the upregulation of the MAP kinase pathway which appears to be involved, however the main mechanism of apoptosis has not been elucidated which may just be directly related to the autophagy induction. Continue reading “Research Update CHF 02643-A MY2: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”